Arrowstreet Capital Limited Partnership raised its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 3.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 992,190 shares of the medical research company’s stock after acquiring an additional 30,051 shares during the quarter. Arrowstreet Capital Limited Partnership owned approximately 0.59% of IQVIA worth $169,208,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in IQV. Ameliora Wealth Management Ltd. purchased a new position in shares of IQVIA during the 4th quarter valued at approximately $25,000. Financial Freedom LLC purchased a new stake in IQVIA during the first quarter worth $25,000. Ascentis Independent Advisors acquired a new stake in IQVIA during the first quarter valued at $25,000. International Assets Investment Management LLC purchased a new position in IQVIA in the fourth quarter valued at $27,000. Finally, Gilpin Wealth Management LLC acquired a new position in shares of IQVIA in the fourth quarter worth about $27,000. Institutional investors and hedge funds own 89.62% of the company’s stock.
Wall Street Analyst Weigh In IQV has been the topic of a number of analyst reports. HSBC restated a “buy” rating and set a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Robert W. Baird increased their price target on IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 1st. Morgan Stanley restated an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Evercore reaffirmed an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $225.71.
Read Our Latest Report on IQVIA
IQVIA Stock Up 0.4% Shares of NYSE IQV opened at $208.22 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The business’s 50 day moving average is $188.23 and its two-hundred day moving average is $187.38. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $247.04. The firm has a market cap of $34.75 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 1.86 and a beta of 1.20.
IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period last year, the business posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year.
IQVIA announced that its Board of Directors has authorized a stock repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its shares are undervalued.
IQVIA Profile (Free Report)
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Articles Five stocks we like better than IQVIA AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Plugging In: How Kinder Morgan Powers Up Profits Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEArrowstreet Capital Limited Partnership Boosts Stock Holdings in Waste Management, Inc. $WM
NEXT HEADLINE »Arrowstreet Capital Limited Partnership Cuts Stake in Nu Holdings Ltd. $NU
Key Takeaways IQVIA's Q2 revenues are expected to rise 6.7% y/y to $4.3 billion, with EPS at $3.02.Commercial solutions growth is expected from drug launches, AI demand and Data-as-a-Service adoption.AI-led workflow gains and backlog conversion are expected to support research and development solutions. IQVIA Holdings Inc. (IQV - Free Report) is set to release second-quarter 2026 results on July 28, before market open.
IQV has a decent earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, with an average surprise of 1.6%.
IQVIA’s Q2 ExpectationsThe Zacks Consensus Estimate for revenues is pegged at $4.3 billion, implying 6.7% year-over-year growth. Growth in the top line is likely to have been stimulated by an efficient use of AI across its business lines.
Revenue gains in the commercial solutions segment are expected to have emanated extensively from rising drug launch activity. Surging demand for the company’s exclusive AI capabilities, tailored AI agents and AI-ready data foundations is anticipated to have added to the growth trajectory.
We expect the rapid adoption of Data-as-a-Service, resulting in multi-year client agreements and enterprise-wide platform adoptions, enhancing commercial intelligence and analytics, to have acted as a major catalyst to this segment’s growth.
For the research and development solutions segment, we expect IQVIA to have leveraged AI to optimize workflow, accelerate study execution and cut down errors, thus improving its revenues. Scheduled conversion of contracted backlogs into revenues over the upcoming months is likely to have contributed to the segment’s growth.
The consensus estimate for earnings per share is $3.02, implying 7.5% year-over-year growth. Enhancement in operational prowess springing from high-margin revenue growth across segments is anticipated to have benefited the bottom line.
What Our Model Says About IQVOur proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV has an Earnings ESP of -2.98% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to ConsiderHere are a few stocks from the broader Medical sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
Alcon (ALC - Free Report) : The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $2.8 billion, indicating 7.3% year-over-year growth. For earnings, the consensus mark is pinned at 77 cents per share, moving up 1.3% from the year-ago quarter’s reported figure. The company beat the consensus estimate in three of the past four quarters and missed once, with an average surprise of 3.7%.
ALC carries an Earnings ESP of +3.13% and a Zacks Rank of 3 at present. The company is scheduled to declare second-quarter 2026 results on Aug. 10.
Waters (WAT - Free Report) : The Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pinned at $1.6 billion, hinting at 3% year-over-year growth. For earnings, the consensus mark is pinned at $3.01 per share, improving 2% from the year-ago quarter’s reported figure. WAT beat the consensus estimate for earnings in the trailing four quarters, with an average surprise of 6%.
WAT has an Earnings ESP of +0.45% and a Zacks Rank of 3 at present. The company is scheduled to declare second-quarter 2026 results on Aug. 4.
The market expects IQVIA Holdings (IQV - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on July 28, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus EstimateThis clinical testing company is expected to post quarterly earnings of $3.02 per share in its upcoming report, which represents a year-over-year change of +7.5%.
Revenues are expected to be $4.3 billion, up 7% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.45% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for IQVIA?For IQVIA, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -2.98%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that IQVIA will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that IQVIA would post earnings of $2.83 per share when it actually produced earnings of $2.90, delivering a surprise of +2.47%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
IQVIA doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Andra AP fonden raised its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 320.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 121,405 shares of the medical research company’s stock after purchasing an additional 92,505 shares during the quarter. Andra AP fonden owned 0.07% of IQVIA worth $20,704,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. J. Safra Sarasin Holding AG lifted its holdings in IQVIA by 174.3% during the 4th quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock worth $2,891,000 after buying an additional 8,151 shares during the last quarter. CWM LLC increased its holdings in shares of IQVIA by 23.9% in the 4th quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock valued at $12,585,000 after acquiring an additional 10,762 shares during the last quarter. Franklin Street Advisors Inc. NC acquired a new stake in shares of IQVIA during the 4th quarter valued at approximately $15,724,000. Calamos Advisors LLC lifted its stake in IQVIA by 268.1% during the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after purchasing an additional 137,441 shares during the last quarter. Finally, HF Advisory Group LLC increased its stake in IQVIA by 1,791.6% during the fourth quarter. HF Advisory Group LLC now owns 154,618 shares of the medical research company’s stock valued at $34,852,000 after purchasing an additional 146,444 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.
Analyst Ratings Changes A number of research analysts have recently issued reports on IQV shares. Morgan Stanley restated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. HSBC reaffirmed a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a report on Thursday, July 9th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Finally, Robert W. Baird increased their price target on IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 1st. Fourteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $225.71.
Get Our Latest Research Report on IQVIA
IQVIA Trading Down 0.9% IQVIA stock opened at $204.33 on Tuesday. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market capitalization of $34.10 billion, a price-to-earnings ratio of 25.32, a PEG ratio of 1.85 and a beta of 1.20. The firm has a 50-day moving average price of $185.66 and a two-hundred day moving average price of $187.72.
IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the business earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.
IQVIA declared that its board has initiated a stock buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.
IQVIA Company Profile (Free Report)
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Read More Five stocks we like better than IQVIA The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEiShares MSCI EAFE Value ETF $EFV Stock Holdings Trimmed by Assetmark Inc.
NEXT HEADLINE »Assetmark Inc. Increases Stock Holdings in Stryker Corporation $SYK
California Public Employees Retirement System increased its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 2.0% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 337,191 shares of the medical research company’s stock after buying an additional 6,563 shares during the period. California Public Employees Retirement System owned 0.20% of IQVIA worth $57,505,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. J. Safra Sarasin Holding AG increased its holdings in shares of IQVIA by 174.3% in the 4th quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock worth $2,891,000 after buying an additional 8,151 shares during the last quarter. CWM LLC lifted its holdings in shares of IQVIA by 23.9% during the 4th quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock worth $12,585,000 after acquiring an additional 10,762 shares during the last quarter. Calamos Advisors LLC grew its position in IQVIA by 268.1% in the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after acquiring an additional 137,441 shares in the last quarter. Franklin Street Advisors Inc. NC purchased a new position in IQVIA in the fourth quarter worth $15,724,000. Finally, HF Advisory Group LLC increased its stake in IQVIA by 1,791.6% in the fourth quarter. HF Advisory Group LLC now owns 154,618 shares of the medical research company’s stock valued at $34,852,000 after acquiring an additional 146,444 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.
IQVIA Stock Performance IQVIA stock opened at $206.26 on Monday. The firm has a fifty day simple moving average of $185.04 and a two-hundred day simple moving average of $187.88. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $247.04. The company has a market capitalization of $34.42 billion, a PE ratio of 25.56, a P/E/G ratio of 1.85 and a beta of 1.20.
IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the previous year, the business earned $2.70 earnings per share. The company’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.
IQVIA announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.
Wall Street Analysts Forecast Growth IQV has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research note on Thursday, July 9th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday. Morgan Stanley restated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Robert W. Baird increased their price target on shares of IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $225.71.
Read Our Latest Stock Analysis on IQVIA
About IQVIA (Free Report)
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
See Also Five stocks we like better than IQVIA Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECalifornia Public Employees Retirement System Has $1.47 Billion Stock Position in Johnson & Johnson $JNJ
NEXT HEADLINE »Johnson & Johnson $JNJ Stock Position Cut by Clifford Swan Investment Counsel LLC
Cantillon Capital Management LLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 11.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,710,896 shares of the medical research company’s stock after selling 230,248 shares during the period. IQVIA comprises approximately 1.9% of Cantillon Capital Management LLC’s holdings, making the stock its 23rd largest position. Cantillon Capital Management LLC owned about 1.01% of IQVIA worth $291,776,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. purchased a new position in shares of IQVIA during the 4th quarter worth approximately $25,000. International Assets Investment Management LLC acquired a new position in IQVIA during the fourth quarter worth $27,000. Gilpin Wealth Management LLC purchased a new position in IQVIA in the fourth quarter worth $27,000. CrossGen Wealth LLC acquired a new stake in IQVIA in the fourth quarter valued at $28,000. Finally, Activest Wealth Management boosted its position in shares of IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.
Analyst Ratings Changes Several research analysts have weighed in on IQV shares. Mizuho upped their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Morgan Stanley reissued an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Evercore reiterated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $225.71.
Get Our Latest Analysis on IQV
IQVIA Stock Performance Shares of IQV stock opened at $206.26 on Monday. The firm has a market cap of $34.42 billion, a P/E ratio of 25.56, a PEG ratio of 1.85 and a beta of 1.20. The firm’s 50-day simple moving average is $185.04 and its 200-day simple moving average is $187.88. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.
IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period in the prior year, the firm posted $2.70 EPS. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.
IQVIA announced that its board has initiated a stock repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.
IQVIA Company Profile (Free Report)
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Stories Five stocks we like better than IQVIA Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBank of New York Mellon Corp Boosts Holdings in First Solar, Inc. $FSLR
SummaryI identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income.My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation.The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.I look beyond retirement favorites such as Realty Income [~5% yield] and Verizon [~6.5% yield], showing how investors can combine reliable income with sustainable growth. Deagreez/iStock via Getty Images
Brent and WTI crude futures (CO1:COM, CL1:COM) were up 17.2% and 15.3%, respectively, this week.
Meanwhile, the S&P VIX Index (VIX), or "fear index," rose 25% to 18.8.
As a result, I believe that dividend stocks
3.46K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of PAGS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, shared recommendations for strengthening the United States as a leading destination for early clinical development during the U.S. House Committee on Energy and Commerce Subcommittee on Health hearing, “Maintaining America's Leadership in Biomedical Innovation: FDA's Role in Advan.
Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV - Free Report) and Penumbra (PEN - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Right now, IQVIA Holdings is sporting a Zacks Rank of #2 (Buy), while Penumbra has a Zacks Rank of #5 (Strong Sell). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that IQV has an improving earnings outlook. But this is just one piece of the puzzle for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
IQV currently has a forward P/E ratio of 16.21, while PEN has a forward P/E of 63.35. We also note that IQV has a PEG ratio of 1.61. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. PEN currently has a PEG ratio of 1.97.
Another notable valuation metric for IQV is its P/B ratio of 5.55. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, PEN has a P/B of 8.51.
These are just a few of the metrics contributing to IQV's Value grade of B and PEN's Value grade of F.
IQV is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that IQV is likely the superior value option right now.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: IQVIA Holdings (IQV - Free Report) Headquartered in Durham, NC., IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speeding innovation and accelerating improvements. IQVIA Holdings operates in more than 100 countries, with around 88,000 employees.
IQV is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 15.92; value investors should take notice.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.01 to $12.80 per share. IQV boasts an average earnings surprise of +1.6%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, IQV should be on investors' short list.
Key Takeaways IQVIA's AI tools, historic R&D backlog and robust free cash flow support its growth outlook.IQV's $34.2B R&D backlog includes $8.9B expected to convert to revenues in the next 12 months.IQVIA faces risks from past industry turmoil, no cash dividend plans and weak liquidity. Shares of IQVIA (IQV - Free Report) have jumped 26.1% over the past year, compared with the industry’s 10.4% decline and the Zacks S&P 500 Composite's 24.3% rise.
1-Year Share Price Performance Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 revenues is $17.3 billion. The metric is expected to gain 5.8% year over year. The same growth rate is anticipated for the top line in 2027. The consensus mark for 2026 EPS is set at $12.8, suggesting a 7.4% increase from that reported in the preceding year. For 2027, the expected growth rate is 11.2%.
Factors That Augur Well for IQV’s SuccessAI Enhances Data Integration: IQVIA’s ability to process information is enhanced by recent advancements in AI, including IQVIA.ai, which provides clients with a single point of access to their AI solutions and enables them to explore a broader portfolio. It has built deep industry trust, as evidenced by 19 of the top 20 global pharma companies utilizing IQV’s distinguished AI agents in their workflows.
Life science clients are highly inclined to select IQVIA’s AI-ready data foundations, including 192 specialized AI agents deployed in the field across 64 use cases in Commercial Solutions and R&D Solutions. Large pharma companies leverage IQVIA’s Data-as-a-Service platform to harmonize global commercial intelligence.
Historic Backlog & Pipeline: IQVIA’s growth trajectory is immensely dictated by its record-breaking R&D Solutions backlog of $34.2 billion. It provides a stream of recurring revenues that enhances long-term visibility. During the first-quarter 2026 earnings call, Ari Bousbib, the CEO and chairman, stated that $8.9 billion of the total backlog is expected to convert into revenues over the next 12 months, marking an 8% rise from the year-ago quarter’s actual.
Immaculate Earnings Quality: As of March 31, 2026, IQV registered $618 million in cash flow from operations and incurred $127 million in CapEx, leading to a free cash flow (FCF) of $491 million. This robust FCF represents 100% of adjusted net income. As a result, IQVIA’s balance sheet accrual ratio was pushed downward to -0.9, wider than the industry’s -0.5, verifying high earnings quality.
Shareholder-Friendly Strategy: IQVIA has demonstrated a strong commitment to returning value to its shareholders through an active share repurchase program. In the past year alone, the company repurchased shares worth $1.24 billion. This substantial buyback not only reduces the total outstanding share count, thereby increasing earnings per share, but also signals management's belief in the intrinsic value of the stock.
Risks Faced by IQVIAPast Industry Turmoil: During the first-quarter 2026 earnings call, management stated that the company is coming out of 3-4 years of industry turbulence. It is primarily fueled by a post-COVID deflationary environment affecting budgets, the IRA under the Biden administration and policies announced/enacted during the Trump regime. These factors collectively forced large pharma to halt discretionary spending that had driven historic organic growth.
No Dividend Discourages Investors: The company currently has no plan to pay out cash dividends on common stock. Payment of dividends in the future depends on factors such as its financial condition, cash requirements and contractual restrictions. Investors seeking cash dividends should avoid buying the IQVIA stock.
Weak Liquidity: IQV ended the first quarter of 2026 with a cash chest of $2.1 billion against a current debt of $1.8 billion. While the current debt was a tad bit lower than cash, the larger picture reveals that IQV’s current liabilities position exceeds its current assets.
As a result, the company ended the aforesaid quarter with a current ratio of 0.75, which has stayed below 1 over the past multiple quarters, hinting at a sustained weak liquidity position. The inability to cover short-term debt does not bode well with investors.
IQV’s Zacks Rank & Stocks to ConsiderThe company has a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the broader Zacks Medical sector are Globus Medical (GMED - Free Report) and Integra LifeSciences (IART - Free Report) , currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Globus Medical has a long-term earnings growth expectation of 10.2%. GMED delivered a trailing four-quarter earnings surprise of 26.3%, on average.
Integra LifeSciences has a long-term earnings growth expectation of 5.9%. IART delivered a trailing four-quarter earnings surprise of 16.8%, on average.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: IQVIA Holdings (IQV - Free Report) Headquartered in Durham, NC., IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speeding innovation and accelerating improvements. IQVIA Holdings operates in more than 100 countries, with around 88,000 employees.
IQV is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 13.99; value investors should take notice.
Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.08 to $12.80 per share. IQV also boasts an average earnings surprise of +1.6%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, IQV should be on investors' short list.
Combining AI-powered media orchestration and human expertise with healthcare-grade data to deliver highly targeted, measurable engagement across HCP and patient audiences.
TORONTO--(BUSINESS WIRE)--StackAdapt (www.stackadapt.com), the leading AI advertising and orchestration platform, today announced a collaboration with IQVIA Digital to advance more relevant and compliant engagement with healthcare audiences. IQVIA Digital’s integrated solutions enable marketers to quickly transform data-driven insights into meaningful, privacy-conscious activation across the healthcare ecosystem.
Through this collaboration, StackAdapt’s programmatic advertising capabilities are now available within Media OS, IQVIA Digital’s end-to-end platform purpose-built for healthcare marketers. This integration enables brands and agencies to activate campaigns with StackAdapt’s best-in-class DSP directly from Media OS, a centralized environment designed around healthcare identities and compliance requirements.
Healthcare marketers have traditionally relied on separate platforms and partners across data, activation, and measurement, often resulting in disconnected workflows and limited visibility into campaign performance. By bringing these components together within Media OS, IQVIA Digital and StackAdapt simplify execution and improve visibility, enabling marketers to reach intended healthcare professionals with enhanced audience fidelity and relevant targeting across channels including CTV, video, display, native, and audio.
“StackAdapt is proud to work closely with IQVIA Digital to enhance the Media OS platform and support healthcare marketers with more connected advertising workflows,” said Mike Novosel, Vice President, Strategic Partnerships at StackAdapt. “Together, we are helping marketers reach healthcare audiences more seamlessly, reduce onboarding complexity, and gain clearer visibility into media measurement.”
For advertisers who prefer to activate campaigns directly within StackAdapt, IQVIA Digital audiences remain seamlessly accessible within the platform. This includes custom HCP audience creation, pre-built audience segments, and integrated healthcare measurement workflows, without requiring additional onboarding, external integrations, or third-party workflows.
For those centralizing campaigns within Media OS, the platform delivers a unified experience that brings together the best of healthcare-specific media and audience intelligence in one place. In addition to DSP-based activation, Media OS provides access to premium endemic healthcare environments, including electronic health record platforms, medical journals, and telehealth settings, as well as broader channels such as email, search, and social.
This release builds on StackAdapt’s growing healthcare offering, where IQVIA Digital’s healthcare intelligence supports HCP engagement, campaign measurement, and reporting capabilities designed for pharmaceutical and healthcare advertisers. StackAdapt works with healthcare organizations like Advanced Diabetes Supply, Mass General Brigham, VSP Vision Care, Indiana University Health, Genomic Health, and US Med.
About StackAdapt
StackAdapt is the leading AI advertising and orchestration platform marketers rely on to drive brand growth and revenue. Built entirely in-house with an easy-to-use interface, StackAdapt unifies programmatic and owned channels—including CTV, DOOH, display, native, audio, email, and more—into one seamless experience. The platform makes it easy to find the right audience, personalize creative, run campaigns, optimize, and measure results in one place. Trusted by the most forward-thinking brands and agencies, StackAdapt combines speed of innovation, deep vertical expertise, and partnership that powers real business growth. For further information, visit www.stackadapt.com.
About IQVIA Digital
IQVIA Digital powers exceptional brand experiences, delivering innovative solutions based on a customer-first, insights-driven, and integrated omnichannel vision. We provide authenticated, data and analytics, innovative fit-for-purpose healthcare technology, and the expertise to enable an effective and adaptable marketing model that drives better quality of care and patient outcomes. IQVIA is the leading global provider of data, advanced analytics, technology solutions and clinical research services for the life sciences industry. Contact us at www.IQVIADigital.com.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise €950,000,000 through an offering of senior notes due 2033 (the “Notes”).
The proceeds from the Notes offering will be used to refinance certain of the Issuer’s existing indebtedness and to pay fees and expenses related to the Notes offering. The consummation of the Notes offering is subject to market and other customary conditions.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.
Forward Looking Statements
Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €950,000,000 in aggregate principal amount of senior notes due 2033 (the “Notes”). The proceeds from the Notes offering will be used to refinance certain of the Issuer’s existing indebtedness and to pay fees and expenses related to the Notes offering.
The Notes will bear interest at a rate of 4.625% per annum and will pay interest semi-annually in arrears on June 15 and December 15 of each year, beginning on December 15, 2026. The Notes will mature on June 15, 2033, unless earlier repurchased or redeemed in accordance with their terms. The issuance of the Notes is expected to occur on or about June 11, 2026, subject to the satisfaction of customary closing conditions.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.
Forward Looking Statements
Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially.
Wiley (NYSE: WLY) and IQVIA (NYSE: IQV) today released Scientific Discovery & AI: The Science-to-Patient Journey, a cross-sector intelligence report drawing on candid dialogue among more than 25 senior leaders from pharma R&D, academic medicine, health systems, AI and technology, publishing and learned societies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615344569/en/
The report summarizes insights from The Summit — an invitation-only, two-day working session co-hosted by Wiley and IQVIA in May 2026. The session opened with a forward-looking perspective on AI and organizational change from Ethan Mollick, Wharton professor, NYT bestselling author of Co-Intelligence, and the forthcoming Co-Existence (October 2026), which set the tone for the dynamic days of discussion. Participants included senior leaders from organizations such as Novo Nordisk, Microsoft, Amazon, Salesforce, American Association for the Advancement of Science (AAAS), American Heart Association, JAMA Network, Johns Hopkins University, University of Michigan, Mapúa University, South Dakota State University, American Society of Mechanical Engineers (ASME), BMJ Group, Japan Advanced Institute of Science and Technology, Queen Mary Intellectual Property Research Institute and Turbine.
A key focus of the report is the gap between AI's technical capability and the health system's ability to absorb it. AI is accelerating every stage of the journey from scientific discovery to patient benefit — but acceleration at one stage can create fracture at the next. Examining each stage of the science-to-patient value chain, participants identified five high-potential directions for the ecosystem:
Decision-first discovery: Embracing AI for large-scale exploration to support wet lab target identification and validation. Structured negative data: Sharing vetted failed experiments to avoid unnecessary repetition. AI agents for patients: Deploying patient-facing AI to help them navigate health systems. Curated aggregation: Combining the scholarly record and real-world data as a trusted alternative to general-purpose AI search. Continuous learning loop: Feeding real-world evidence back into trial design, clinical guidelines and upstream research. “For AI to deliver its full promise in healthcare and science, all parts of the system must be engaged. AI has vastly increased the speed at which we can resolve molecular identities and surface new candidates — but if the publishing model, clinical development infrastructure and real-world adoption don’t keep pace, those discoveries won’t reach patients as quickly as they should,” said Armughan Rafat, Wiley SVP, Chief AI & Data Analytics Officer. “That’s the conversation Wiley and IQVIA have convened. We didn’t set out to produce consensus, but rather to surface an honest diagnosis.”
"AI is already reshaping every stage of the healthcare value chain, but the real opportunity lies in connecting those stages into a continuous learning system. What emerged from The Summit is a clear need to move beyond isolated innovation toward integrated evidence ecosystems – where clinical research, real-world data and advanced analytics work in unison. By closing the loop between discovery, development and real-world outcomes, we can accelerate not just insight generation, but meaningful impact for patients," said Rob Kotchie, IQVIA President, Real World Evidence & Clinical Technology Solutions.
The report is also candid about identifying existing structural limits. A consistent finding across every stage of the value chain is that incentives are an impediment: the system rewards behaviors that don’t always optimize for science, patients or long-term progress. Addressing such misalignment requires collaboration across actors and structural change.
Scientific Discovery & AI: The Science-to-Patient Journey is available now at this link. The reportmaps the findings from The Summit across four stages of the science-to-patient value chain: Discovery & Early Research, Clinical Development & Evidence Generation, Validation & Dissemination and Real-World Adoption & Patient Impact.
Together, Wiley and IQVIA span the full value chain — from evidence creation and peer review through real-world clinical application — and are strongly positioned to connect the stakeholders who need to be in conversation.
About Wiley
Wiley (NYSE: WLY) is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.
About IQVIA
IQVIA NYSE:IQV is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Category: All Corporate News
View source version on businesswire.com: https://www.businesswire.com/news/home/20260615344569/en/
HOBOKEN, N.J.--(BUSINESS WIRE)--Wiley (NYSE: WLY) and IQVIA (NYSE: IQV) today released Scientific Discovery & AI: The Science-to-Patient Journey, a cross-sector intelligence report drawing on candid dialogue among more than 25 senior leaders from pharma R&D, academic medicine, health systems, AI and technology, publishing and learned societies. The report summarizes insights from The Summit — an invitation-only, two-day working session co-hosted by Wiley and IQVIA in May 2026. The sessi.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: IQVIA Holdings (IQV - Free Report) Headquartered in Durham, NC., IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speeding innovation and accelerating improvements. IQVIA Holdings operates in more than 100 countries, with around 88,000 employees.
IQV is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. IQV has a Momentum Style Score of B, and shares are up 7.3% over the past four weeks.
Eight analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.09 to $12.80 per share. IQV boasts an average earnings surprise of +1.6%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, IQV should be on investors' short list.
Veeva Systems (VEEV 1.72%) joins the S&P 500 on May 7. The news, which came out on April 30, drove the life sciences cloud solutions company's shares higher in early trading on May 1. Veeva will replace Coterra Energy, which is being bought up by Devon Energy.
Veeva is a software provider that specializes in life sciences, and it is moving away from legacy partnerships toward platform independence, a move that could bring huge rewards but also has some inherent risks.
Here are three reasons to buy Veeva Systems and one reason not to right now.
Image source: Getty Images.
1. Its Migration to the Vault CRM system For years, Veeva's commercial software sat on top of Salesforce's (CRM 0.65%) infrastructure. While this enabled rapid scaling, it limited Veeva's control over its technical destiny and required significant licensing payments to Salesforce. The company is now in the middle of a multi-year project to move its entire customer base to its proprietary Vault platform.
So far, the progress has gone well. With more than 125 customers -- including several of the world's largest pharmaceutical companies -- already on its Vault content relationship management (CRM) system, the company has shown it can handle the technical complexity of data migration without disrupting its clients' critical sales operations.
This transition is expected to be largely complete by 2029, at which point Veeva should enjoy significantly higher gross margins and total control over its innovation cycle, no longer beholden to the updates or pricing of an outside partner.
2. The growth of Veeva's development cloud While many investors focus on the CRM side, the back end of the business -- clinical trials, regulatory compliance, and safety monitoring -- is arguably the more durable growth engine. Modern drug development is becoming increasingly complex, requiring the management of massive datasets across global sites, and Veeva's safety modules are becoming the industry standard. Because these tools are deeply integrated into the regulatory filing process, they are incredibly sticky.
Once a pharmaceutical giant adopts Veeva Vault for its clinical trial data, the cost and operational risk of switching to a competitor are prohibitively high. This creates a moat that few other software-as-a-service (SaaS) companies can claim, providing a predictable, growing stream of subscription revenue decoupled from the broader economic cycle.
In December, the company released its first artificial intelligence (AI) agents for CRM and commercial content. In fiscal 2026, the company grew subscription revenue by 17% to $2.68 billion, outpacing overall revenue growth.
Today's Change
(
-1.72
%) $
-2.78
Current Price
$
158.77
3. Strong revenue, margin growth In fiscal 2026, the company reported revenue of $3.2 billion, up 16%, and earnings per share of $5.44, up 25.9%. In 2027, it is predicting revenue of $3.59 billion to $3.6 billion, up 12.4% at the midpoint, and net income of about $1.59 billion, up 75%.
Even as it invested heavily in platform migration and expansion into new markets such as medtech and consumer products, the company maintained a non-GAAP (generally accepted accounting principles) operating margin of 44.9% in 2026, up 29 basis points from 2025. In an era where many growth-oriented tech companies struggle to find a path to consistent profitability, Veeva generates significant free cash flow.
The company's $2 billion share buyback program, announced in early January, underscores management's belief that the stock remains undervalued relative to its long-term earnings power. This combination of growth, high margins, and capital return makes it a rare triple threat for a diversified portfolio.
One concern: A former friend is now a foe Veeva has turned Salesforce from a partner into a direct competitor. Salesforce has not conceded the life sciences vertical; instead, it has launched its own dedicated Life Sciences Cloud to compete directly for the enterprise accounts Veeva currently holds.
While Veeva has a decade-long head start in specialized functionality, Salesforce has deeper pockets and an existing presence in many of these companies' other departments (such as human relations or general marketing). If Salesforce or other emerging competitors such as IQVIA (IQV 0.94%) can offer functionality at a lower total cost of ownership, Veeva may find itself in a price war.
This could lead to a compression of the premium valuation multiples that the stock currently commands, as the market begins to view Veeva as a more traditional enterprise software company rather than an untouchable monopoly in the life sciences space.
A moat of familiarity and expertise Veeva's shares have declined more than 22% so far this year because of concerns about the software sector and Veeva's high-profile transition. However, the early results show the company is managing it well, and thanks to the share drop, the stock is trading at a forward price-to-earnings ratio of only 19.6, a reasonable valuation for a growth stock with high margins. Over the past decade, it has grown its annual revenue by 487% and its annual operating margin by 49%.
The company has an early-mover edge in life sciences. Its clients, which include 10 of the top 20 pharmaceutical companies, are demonstrating comfort with the company's systems. Veeva's addition to the S&P 500 will also attract new investors, including index funds that track the S&P 500.
IQVIA Holdings (IQV) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.83 per share. This compares to earnings of $2.7 per share a year ago.
Key Takeaways IQV Q1 adjusted EPS of $2.90 beat the estimate of $2.83; revenues of $4.15B rise 8.4% y/y.IQVIA Commercial Solutions revenues were $1.75B, up 11.6% y/y, led by patient and analytics demand.IQV R&D Solutions posted $34.2B in backlog; $2.5B in net bookings and 1.04X book-to-bill in Q1. IQVIA Holdings Inc. (IQV - Free Report) has posted first-quarter 2026 adjusted earnings of $2.90 per share, beating the Zacks Consensus Estimate of $2.83 by 2.5%. Revenues came in at $4.15 billion, topping the consensus mark of $4.08 billion by 1.6%.
Results improved year over year, with adjusted diluted earnings per share up 7.4% and revenues rising 8.4%. The quarter benefited from better-than-expected organic growth across the business, supported by strengthening demand indicators, including a $34.2-billion contracted backlog in the Research & Development Solutions business.
IQV's Commercial Solutions Growth Leads the QuarterCommercial Solutions delivered the sharpest top-line momentum in the quarter. Segmental revenues were $1.75 billion, increasing 11.6% on a reported basis and 8.5% at constant currency.
Management highlighted notable strength across patient solutions, analytics and consulting, and commercial engagement services. The company also pointed to growing traction in AI-enabled offerings, suggesting product innovation is contributing to sales performance alongside broader market demand.
IQVIA's R&D Franchise Shows Healthier Demand SignalsResearch & Development Solutions revenues were $2.40 billion, up 6.2% on a reported basis and 4.2% at constant currency. Excluding reimbursed expenses, R&D Solutions revenues increased 6.6% reported, reflecting healthier underlying service growth.
Beyond reported revenues, the bookings picture remained constructive. Net new bookings were $2.5 billion, with a first-quarter book-to-bill ratio of 1.04X and a trailing-12-month ratio of 1.11X. The company also expects $8.9 billion of contracted work to convert into revenues over the next 12 months, indicating 7.6% year-over-year growth, offering a clearer line of sight into near-term demand.
IQV's Profit Engine Supports Cash ConversionProfitability remained solid in the quarter, with adjusted EBITDA of $932 million, up 5.5% year over year. GAAP net income attributable to IQVIA was $274 million, reflecting continued earnings power alongside ongoing non-GAAP addbacks tied to restructuring and acquisition-related items.
Cash generation was a key positive. The operating cash flow rose 9% year over year to $618 million, while the free cash flow increased 15% to $491 million. Notably, the free cash flow equaled 100% of adjusted net income, underscoring strong conversion and disciplined working-capital management.
IQVIA's 2026 Outlook Mixes Stability With UpsideIQVIA reaffirmed its 2026 revenue guidance of $17.15-$17.35 billion and maintained its adjusted EBITDA outlook of $3.975-$4.025 billion, signaling confidence in the demand environment and delivery execution across both segments.
The company raised its full-year adjusted diluted earnings per share forecast to $12.65-$12.95, pointing to better operating performance than previously expected. The outlook assumes 150 basis points of acquisition contribution and an estimated 100 basis points of foreign-exchange tailwind, based on exchange rates as of May 4, 2026.
IQV's Balance Sheet & Capital Returns Stay in FocusIQVIA ended the quarter with $1.95 billion in cash and cash equivalents, and total debt of $15.83 billion, translating to net debt of $13.89 billion. The net leverage ratio was 3.62X trailing 12-month adjusted EBITDA, providing context for financial flexibility as the company balances investment needs with shareholder returns.
Capital allocation remained active. IQVIA repurchased $552 million worth of common stock during the quarter and had $1.22 billion remaining under its authorization as of March 31, 2026, reinforcing management’s continued emphasis on returning capital while maintaining leverage within its targeted framework.
IQV carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Earnings SnapshotVerisk Analytics, Inc. (VRSK - Free Report) reported first-quarter 2026 diluted adjusted earnings per share of $1.82, beating the Zacks Consensus Estimate of $1.76 by 3.4%. The figure increased 5.2% from the year-ago quarter.
Revenues came in at $782.6 million, topping the consensus mark of $775.9 million by 0.9% and rising 3.9% year over year. Organic constant-currency revenue growth was 4.7%, supported by continued momentum across the Insurance business.
Automatic Data Processing, Inc. (ADP - Free Report) posted third-quarter fiscal 2026 adjusted earnings per share of $3.37, beating the Zacks Consensus Estimate of $3.28 by 2.7%. The metric increased 10.1% from the year-ago quarter.
Total revenues came in at $5.94 billion, topping the consensus mark of $5.86 billion by 1.4% and rising 7% year over year. Operationally, Employer Services client revenue retention and overall client satisfaction reached record highs for the third quarter.
We initiated four new positions in Q1, an above-average pace of activity. We also used the increased volatility to upgrade overall portfolio quality. Our three largest new positions were Amazon.com, Universal Music Group and IQVIA Holdings. In addition to sales of Humana and PayPal, we also exited our positions in social technology leader Meta Platforms and beverages company Diageo.
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amkor Technology Target of Unusually Large Options Trading (NASDAQ:AMKR)MarketBeat
Amkor Technology, Inc. (NASDAQ:AMKR - Get Free Report) was the recipient of unusually large options trading on Friday. Investors acquired 12,436 call options on the company. This is an increase of approximately 48% compared to the average volume of 8,425 call options.
NASDAQ:AMKR
Read Amkor Technology Target of Unusually Large Options Trading (NASDAQ:AMKR)
3 hours ago
CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 SharesMarketBeat
CocaCola Company (The) (NYSE:KO - Get Free Report) EVP Jennifer Mann sold 23,984 shares of the firm's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $83.41, for a total value of $2,000,505.44. Following the completion of the transaction, the executive vice president owned 157,400 shares of the company's stock, valued at approximately $13,128,734. The trade was a 13.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
NYSE:KO
Read CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 Shares
Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 324
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: IQVIA Holdings (IQV - Free Report) Headquartered in Durham, NC., IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speeding innovation and accelerating improvements. IQVIA Holdings operates in more than 100 countries, with around 88,000 employees.
IQV is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 13.63; value investors should take notice.
Five analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.04 to $12.73 per share. IQV boasts an average earnings surprise of +1.6%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, IQV should be on investors' short list.
IQVIA earns a Buy rating as the market underappreciates its AI-driven Commercial Solutions segment and unique healthcare data assets. AI is a tailwind, not a threat, with 19 of the top 20 pharma companies using IQV's AI agents and workflows. Commercial Solutions segment grew 11.6% year-over-year, outpacing the traditional CRO segment and driving margin expansion.
Key Takeaways IQVIA shares rose 15.3% in a year, outperforming the industry's drop of 7.1%.IQVIA posted a record $34.2B backlog; $8.9B should convert to revenues in the next 12 months.IQV deployed 192 AI agents in 64 use cases; 19 of the top 20 pharma firms use them in workflows. Shares of IQVIA Holdings Inc. (IQV - Free Report) have risen 15.3% over the past year against the industry’s 7.1% fall.
IQV’s revenues are expected to increase 5.7% and 5.9% year over year in 2026 and 2027, respectively. Earnings are anticipated to rise 7.2% in 2026 and 11.1% in 2027.
Factors That Augur Well for IQV’s SuccessRecord Backlog: During the first quarter of 2026 earnings call, Ari Bousbib, the CEO, stated that IQV’s backlog reached a new record of $34.2 billion. Out of the total backlog, $8.9 billion is anticipated to convert to revenues over the upcoming 12 months. It represents approximately 8% year-over-year growth compared with the recast numbers from the preceding year.
AI Fueling Demand: Rapid AI adoption by IQVIA’s clients has increased demand for the company’s differentiated, health-grade capabilities. The company has deployed 192 specialized AI agents across 64 distinct use cases. Importantly, 19 out of the top 20 pharma companies are leveraging these agents within their workflows. IQV successfully managed to secure multi-year partnerships utilizing AI-led data foundations and Data-as-a-Service platforms with Pfizer, Boehringer Ingelheim and many more.
Active Share Repurchase: IQVIA has demonstrated a strong commitment to returning value to its shareholders through an active share repurchase program. In 2025, the company repurchased shares worth $1.24 billion. This substantial buyback not only lowers the total outstanding share count, thereby increasing earnings per share, but also signals management's confidence in the intrinsic value of the stock.
Risks Faced by IQVIAWeak Liquidity Profile: IQVIA’s current ratio at the end of the first quarter of 2026 was 0.75, lower than the industry’s 1.79. A current ratio of less than 1 highlights the fact that the company may have problems paying off its short-term obligations.
Image Source: Zacks Investment Research
No Dividends: The company neither pays dividends nor currently has any plans to do so in the future. Payment of dividends in the future depends on factors such as its financial condition, cash requirements and contractual restrictions. Investors seeking cash dividends should avoid buying IQVIA stock.
IQV’s Zacks Rank & Stocks to ConsiderThe company has a Zacks Rank #3 (Hold) at present.
Some top-ranked stocks from the broader Zacks Medical sector are Bayer (BAYRY - Free Report) and Alignment Healthcare (ALHC - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bayer has a long-term earnings growth expectation of 2.5%. BAYRY delivered a trailing four-quarter earnings surprise of 23.6%, on average.
Alignment Healthcare has a long-term earnings growth expectation of 38%. ALHC delivered a trailing four-quarter earnings surprise of 198.8%, on average.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: IQVIA Holdings (IQV - Free Report) Headquartered in Durham, NC., IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speeding innovation and accelerating improvements. IQVIA Holdings operates in more than 100 countries, with around 88,000 employees.
IQV is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 14.26; value investors should take notice.
For fiscal 2026, eight analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.09 to $12.78 per share. IQV boasts an average earnings surprise of +1.6%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, IQV should be on investors' short list.
IQVIA Holdings Inc. (âIQVIAâ) (NYSE: IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the âIssuerâ), intends to raise â¬950,000,000 t
It has been about a month since the last earnings report for IQVIA Holdings (IQV - Free Report) . Shares have added about 3.2% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is IQVIA due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
IQVIA Surpasses Q1 Earnings EstimatesIQVIA Holdings reported impressive first-quarter 2026 results, wherein earnings and revenues beat the Zacks Consensus Estimate. IQV has posted first-quarter 2026 adjusted earnings of $2.90 per share, beating the Zacks Consensus Estimate of $2.83 by 2.5%. Revenues came in at $4.15 billion, topping the consensus mark of $4.08 billion by 1.6%.
Results improved year over year, with adjusted diluted earnings per share up 7.4% and revenues rising 8.4%. The quarter benefited from better-than-expected organic growth across the business, supported by strengthening demand indicators, including a $34.2-billion contracted backlog in the Research & Development Solutions business.
IQV's Commercial Solutions Growth Leads the QuarterCommercial Solutions delivered the sharpest top-line momentum in the quarter. Segmental revenues were $1.75 billion, increasing 11.6% on a reported basis and 8.5% at constant currency.
Management highlighted notable strength across patient solutions, analytics and consulting, and commercial engagement services. The company also pointed to growing traction in AI-enabled offerings, suggesting product innovation is contributing to sales performance alongside broader market demand.
IQVIA's R&D Franchise Shows Healthier Demand SignalsResearch & Development Solutions revenues were $2.40 billion, up 6.2% on a reported basis and 4.2% at constant currency. Excluding reimbursed expenses, R&D Solutions revenues increased 6.6% reported, reflecting healthier underlying service growth.
Beyond reported revenues, the bookings picture remained constructive. Net new bookings were $2.5 billion, with a first-quarter book-to-bill ratio of 1.04X and a trailing-12-month ratio of 1.11X. The company also expects $8.9 billion of contracted work to convert into revenues over the next 12 months, indicating 7.6% year-over-year growth, offering a clearer line of sight into near-term demand.
IQV's Profit Engine Supports Cash ConversionProfitability remained solid in the quarter, with adjusted EBITDA of $932 million, up 5.5% year over year. GAAP net income attributable to IQVIA was $274 million, reflecting continued earnings power alongside ongoing non-GAAP addbacks tied to restructuring and acquisition-related items.
Cash generation was a key positive. The operating cash flow rose 9% year over year to $618 million, while the free cash flow increased 15% to $491 million. Notably, the free cash flow equaled 100% of adjusted net income, underscoring strong conversion and disciplined working-capital management.
IQVIA's 2026 Outlook Mixes Stability With UpsideIQVIA reaffirmed its 2026 revenue guidance of $17.15-$17.35 billion and maintained its adjusted EBITDA outlook of $3.975-$4.025 billion, signaling confidence in the demand environment and delivery execution across both segments.
The company raised its full-year adjusted diluted earnings per share forecast to $12.65-$12.95, pointing to better operating performance than previously expected. The outlook assumes 150 basis points of acquisition contribution and an estimated 100 basis points of foreign-exchange tailwind, based on exchange rates as of May 4, 2026.
IQV's Balance Sheet & Capital Returns Stay in FocusIQVIA ended the quarter with $1.95 billion in cash and cash equivalents, and total debt of $15.83 billion, translating to net debt of $13.89 billion. The net leverage ratio was 3.62X trailing 12-month adjusted EBITDA, providing context for financial flexibility as the company balances investment needs with shareholder returns.
Capital allocation remained active. IQVIA repurchased $552 million worth of common stock during the quarter and had $1.22 billion remaining under its authorization as of March 31, 2026, reinforcing management’s continued emphasis on returning capital while maintaining leverage within its targeted framework.
How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a flat trend in estimates revision.
VGM ScoresCurrently, IQVIA has a average Growth Score of C, a score with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a score of B on the value side, putting it in the second quintile for value investors.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook IQVIA has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerIQVIA is part of the Zacks Medical - Instruments industry. Over the past month, OPKO Health (OPK - Free Report) , a stock from the same industry, has gained 30.4%. The company reported its results for the quarter ended March 2026 more than a month ago.
OPKO Health reported revenues of $124.2 million in the last reported quarter, representing a year-over-year change of -17.1%. EPS of -$0.07 for the same period compares with -$0.10 a year ago.
For the current quarter, OPKO Health is expected to post a loss of $0.08 per share, indicating a change of +57.9% from the year-ago quarter. The Zacks Consensus Estimate has changed -2.6% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for OPKO Health. Also, the stock has a VGM Score of F.
